We systematically screened data from the FAERS database covering from Q1 2004 to Q2 2024, specifically focusing on reports of cholecystitis and cholelithiasis where GLP-1 RAs were identified as the primary suspect drug. Here, GLP1R is linked to Cholecystitis.